Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Promising drug combo targets tough childhood cancers in adults

NCT ID NCT01858168

First seen Jan 10, 2026 · Last updated May 24, 2026 · Updated 19 times

Summary

This study tested the safety and best dose of a drug combination (olaparib plus temozolomide) in 49 adults with Ewing sarcoma or rhabdomyosarcoma that had come back or spread after standard chemotherapy. The goal was to find a dose that could be given safely and to see if the combination might help shrink tumors. This was an early-phase trial, so it focused on safety and dosing, not on proving the treatment works.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHABDOMYOSARCOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Boston Children's Hospital

    Boston, Massachusetts, 02115, United States

  • Brigham and Women's Hospital

    Boston, Massachusetts, 02215, United States

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • St. Jude's Children's Research Hospital

    Memphis, Tennessee, 38105, United States

Conditions

Explore the condition pages connected to this study.